BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.

ABSTRACT:

Background

The introduction of pertuzumab has greatly improved pathological complete response (pCR) rates in HER2-positive breast cancer, yet effects on long-term survival have been limited and it is uncertain which patients derive most benefit. In this study, we determine the prognostic value of BluePrint subtyping in HER2-positive breast cancer. Additionally, we evaluate its use as a biomarker for predicting response to trastuzumab-containing neoadjuvant chemotherapy with or without pertuzumab.

Methods

From a cohort of patients with stage II-III HER2-positive breast cancer who were treated with neoadjuvant chemotherapy and trastuzumab with or without pertuzumab, 836 patients were selected for microarray gene expression analysis, followed by readout of BluePrint standard (H

SUBMITTER: Liefaard MC 

PROVIDER: S-EPMC10280902 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature